Decision on EU marketing authorisation for this population expected by September 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
The initiative will focus on advocating for cleaner air
Subscribe To Our Newsletter & Stay Updated
